Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $7.20.

Several analysts have recently commented on the stock. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. Stephens increased their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. HC Wainwright boosted their target price on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Finally, Guggenheim lifted their price objective on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th.

Pyxis Oncology Stock Down 7.2%

Shares of PYXS opened at $1.42 on Friday. Pyxis Oncology has a 12-month low of $0.83 and a 12-month high of $5.55. The firm has a market capitalization of $88.41 million, a price-to-earnings ratio of -0.89 and a beta of 1.45. The stock’s 50-day moving average price is $1.60 and its 200 day moving average price is $2.46.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PYXS. Maia Wealth LLC acquired a new position in Pyxis Oncology in the fourth quarter valued at about $25,000. Engineers Gate Manager LP bought a new position in shares of Pyxis Oncology during the 4th quarter valued at about $26,000. Fox Run Management L.L.C. acquired a new position in shares of Pyxis Oncology in the 4th quarter valued at approximately $26,000. Catalyst Funds Management Pty Ltd bought a new stake in Pyxis Oncology during the 2nd quarter worth approximately $26,000. Finally, Avanza Fonder AB acquired a new stake in Pyxis Oncology during the 4th quarter worth approximately $31,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.